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Background: In apoptosis, proteolysis by caspases is the primary mechanism for both initiation and execution
of programmed cell death (PCD). In contrast, the impact of proteolysis on the regulation and execution of
caspase-independent forms of PCD (programmed necrosis, necroptosis) is only marginally understood. Likewise,
the identity of the involved proteases has remained largely obscure. Here, we have investigated the impact of
proteases in TNF-induced necroptosis.
Results: The serine protease inhibitor TPKC protected from TNF-induced necroptosis in multiple murine and
human cells systems whereas inhibitors of metalloproteinases or calpain/cysteine and cathepsin proteases had no
effect. A screen for proteins labeled by a fluorescent TPCK derivative in necroptotic cells identified HtrA2/Omi
(a serine protease previously implicated in PCD) as a promising candidate. Demonstrating its functional impact,
pharmacological inhibition or genetic deletion of HtrA2/Omi protected from TNF-induced necroptosis. Unlike in
apoptosis, HtrA2/Omi did not cleave another protease, ubiquitin C-terminal hydrolase (UCH-L1) during
TNF-induced necroptosis, but rather induced monoubiquitination indicative for UCH-L1 activation.
Correspondingly, pharmacologic or RNA interference-mediated inhibition of UCH-L1 protected from TNF-induced
necroptosis. We found that UCH-L1 is a mediator of caspase-independent, non-apoptotic cell death also in
diseased kidney podocytes by measuring cleavage of the protein PARP-1, caspase activity, cell death and cell
morphology. Indicating a role of TNF in this process, podocytes with stably downregulated UCH-L1 proved
resistant to TNF-induced necroptosis.
Conclusions: The proteases HtrA2/Omi and UCH-L1 represent two key components of TNF-induced necroptosis,
validating the relevance of proteolysis not only for apoptosis, but also for caspase-independent PCD. Since
UCH-L1 clearly contributes to the non-apoptotic death of podocytes, interference with the necroptotic properties
of HtrA2/Omi and UCH-L1 may prove beneficial for the treatment of patients, e.g. in kidney failure.
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Cleavage of proteins by caspases is essential for the apop-
totic elimination of unwanted or potentially harmful cells
and thus for the survival and homeostasis of multicellular
organisms [1]. Whereas apoptosis represents the primary
route to programmed cell death (PCD) in most phy-
siological settings, non-apoptotic, caspase-independent* Correspondence: dadam@email.uni-kiel.de
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reproduction in any medium, provided the orforms of PCD have been discovered which can act as a
backup mechanism to allow cell suicide under condi-
tions where the caspase machinery is inhibited (e.g. in
apoptosis-resistant tumor cells or after virus infection)
[2,3]. As the main mode of caspase-independent PCD,
programmed necrosis (also termed “necroptosis” when
mediated by the kinases RIPK1 and RIPK3) has emerged
as an important and physiologically relevant response in
vital processes, e.g. the elimination of chondrocytes,
virus infection, bacterial infection [4] or the homeostasis
of T cell populations [5]. Moreover, programmed ne-
crosis has been described to trigger pathophysiologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nation from pancreatic islets/development of diabetes,
loss of hypertrophic cardiomyocytes during heart failure
[7], Crohn’s disease [8], acute pancreatitis, ischemic
injury and inflammation [4,9,10].
At the molecular level, the signaling pathways of pro-
grammed necrosis and necroptosis are still incompletely
understood. The best studied model of programmed ne-
crosis, necroptosis mediated by the 55 kDa tumor necrosis
factor (TNF) receptor (TNF-R1) depends on the activity
of the kinases RIPK1 and RIPK3 and the protein MLKL.
These essential core components relay the necroptotic sig-
nal to further downstream effectors such as PGAM5L/S
and Drp-1, thereby inducing mitochondrial fragmentation
[11]. Independently, production of reactive oxygen spe-
cies, e.g. by mitochondria or by the NADPH oxidase
Nox1, lipid peroxidation, enzymes of the energy meta-
bolism, the deubiquitinase CYLD and the Bcl-2 family
member Bmf have been suggested as further mediators of
necroptosis [12]. In addition, our own group has pre-
viously identified the sphingolipid ceramide as a key
effector of TNF-induced necroptosis [13,14]. Moreover,
we have been able to show in a very recent study that, in
contrast to previous assumptions [12], TNF-induced
necroptosis is not mediated by the “PARP pathway”
(a signaling cascade that involves overactivation of the
DNA repair enzyme PARP-1, depletion of intracellular
NAD+ and ATP, release of apoptosis-inducing factor from
mitochondria, DNA fragmentation and cell death). Rather,
necroptosis induced by TNF and the PARP pathway
represent two independent and distinct routes to pro-
grammed necrosis [15].
In contrast to apoptosis, which depends essentially on
the proteolytic activity of caspases, the role of proteolytic
events for both regulation and execution of necroptosis/
programmed necrosis is considerably less well charac-
terized. Aside from a negative regulation of necroptosis
by caspase-8 via cleavage and inactivation of RIPK1 [3],
lysosomal proteases such as cathepsin B, D, calpains,
granzymes and cys-cathepsins can substitute for caspases
in some, but not all forms of programmed necrosis [16].
Also, the endoplasmic reticulum (ER) can induce pro-
grammed necrosis in response to cellular stress or un-
controlled release of calcium through calpain proteases
[16,17]. Several groups (including our own) have inde-
pendently observed that serine protease inhibitors such as
tosyl phenylalanyl chloromethyl ketone (TPCK) can in-
hibit both necroptosis/programmed necrosis [18-21] and
apoptosis [22]. For apoptosis, serine proteases have been
found to complement or augment the function of cas-
pases, e.g. granzyme B can stimulate apoptosis by cleavage
of several procaspases, the pro-apoptotic protein Bid, or
inhibitor of caspase-activated DNAse (ICAD) in cyto-
toxic T lymphocytes and natural killer cells [22]. Fornecroptosis/programmed necrosis, the identity of the
relevant serine proteases and that of their substrates has
remained largely obscure.
Here, we have identified the serine protease HtrA2/Omi
as a key protease that mediates TNF-induced necroptosis.
HtrA2/Omi is the mammalian homologue of the bacterial
HtrA endoprotease and highly conserved from bacteria to
mammalians. In the latter, HtrA2/Omi is involved in the
degradation of misfolded proteins during conditions of
cellular stress (e.g. ER stress, heat shock and ischemia/
reperfusion) [23]. Deletion of HtrA2/Omi or mutations
affecting its activity have been associated with neuro-
degeneration and Parkinson’s disease in mouse models
[24] and patients [25]. In response to apoptotic stimuli,
HtrA2/Omi is released from mitochondria into the cyto-
plasm, where it promotes apoptosis by binding and
inhibiting IAP (inhibitor of apoptosis) proteins, thus
releasing active caspases from their natural inhibitors.
Independently, HtrA2/Omi degrades IAPs, the caspase-8
inhibitor Pea-15 and the anti-apoptotic protein HAX-1
through its serine protease activity, further promoting
apoptosis [25].
In contrast to apoptosis, the molecular details of how
HtrA2/Omi participates in necroptotic signaling are
largely unknown. It has been reported that HtrA2/Omi
can mediate caspase-independent PCD via its serine
protease activity, e.g. upon interleukin-3 deprivation of
the mouse pro-B cell line Ba/F3 [25], in imatinib-treated
human leukemic cells [26], or in cytomegalovirus infec-
tion [27]. However, except for one study reporting clea-
vage and inactivation of RIPK1 by HtrA2/Omi [25], the
substrates of HtrA2/Omi in necroptosis/programmed
necrosis are unknown.
In the course of this study, we have identified ubiqui-
tin C-terminal hydrolase (UCH-L1) as a second protease
which participates in TNF-induced necroptosis down-
stream of HtrA2/Omi. UCH-L1 belongs to the family of
cysteine proteases and functions as a deubiquitinase
which generates, binds and stabilizes ubiquitin mono-
mers, and thus can replenish the cellular monoubiquitin
pool. Independently, UCH-L1 may act as an ubiquitin
ligase [28], and may even have functions independent of
the ubiquitin-proteasome system [29]. UCH-L1 is mainly
expressed in neuronal tissues (very abundantly in the
brain), in synovial membranes and in cells of the testis,
ovaries, and kidney [28,30]. Abnormal expression of
UCHL1 is found in many forms of cancer, including
lung, colorectal, and pancreatic cancers, and may be re-
lated to tumor progression [29]. Aberrant expression of
UCH-L1 has also been associated with neurodegene-
rative diseases, ischemic and traumatic brain injury [31].
Accordingly, and similar to HtrA2/Omi, mutations in
UCH-L1 have been associated with Parkinson’s disease,
as well as with other neurodegenerative disorders such
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UCH-L1 is involved in podocyte injury and proteinuria
in the kidney, possibly mediated through activation of
the transcription factor NF-κB [30,31]. However, the true
in vivo functions as well as the physiological substrates
of UCHL1 remain unclear at present [29].
In this study, we have investigated the role of proteases
in the regulation of TNF-induced necroptosis and esta-
blish two non-caspase proteases, the serine protease
HtrA2/Omi and the deubiquitinase UCH-L1 as regulators
of this form of PCD, simultaneously identifying two novel
potential targets for therapeutic intervention.
Results
Inhibition of serine proteases, but not metalloproteases,
cathepsin or calpain/cysteine proteases protects from
TNF-induced necroptosis
In a first set of experiments, we investigated the effects of
different protease inhibitors on TNF-induced necroptosis.
As shown in Figure 1A, TPCK, an inhibitor of chymotryp-
sin-like serine proteases significantly protected murine
L929Ts fibrosarcoma cells (a tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-sensitive L929 subline
derived in our laboratory [33]) from TNF-induced ne-
croptosis, consistent with a previous study in parental
L929 cells [21]. We found that TPKC also significantly
diminished TNF-induced necroptosis in murine NIH3T3
fibroblasts cells as well as in human leukemic Jurkat
T cells and in human HT-29 colorectal adenocarcinoma
cells (Figure 1A) as further established cell systems for
necroptosis [14,15,34]. We next investigated whether
TNF-induced necroptosis is regulated by metallopro-
teinases. However, TAPI-1, an inhibitor of TACE (TNF-α
converting enzyme, ADAM17) and other metallopro-
teinases, as well as GM 6001 and marimastat, two further
broad-spectrum inhibitors of matrix metalloproteinases,
had no inhibitory effect on TNF-induced necroptosis in
L929Ts or NIH3T3 cells (Figure 1B). Likewise, inhibitors
of the cysteine proteases cathepsin B/L (zFA-fmk), ca-
thepsin B (Ca-074 Me), cathepsin L (zFF-fmk), as well as
the broad-spectrum calpain/cysteine protease inhibitor
E-64 did not protect L929Ts cells from TNF-induced
necroptosis (Figure 1C), in line with previous findings
[14,15,33]. In summary, these results suggest that chymo-
trypsin-like serine proteases participate in TNF-induced
necroptosis in a cell type- and species-independent man-
ner whereas inhibition of metalloproteinases, cathepsins
and calpain/cysteine proteases has no major impact in this
form of PCD.
A screen for serine proteases relevant in TNF-induced
necroptosis reveals HtrA2/Omi as a promising candidate
To identify the TPCK-sensitive serine protease(s) that
regulate TNF-dependent necroptosis, we adapted anapproach that had been previously employed to success-
fully identify proteases relevant for endoplasmic reticulum
(ER) stress-induced caspase-independent PCD [35]. For
this purpose, we induced necroptosis in L929Ts cells
(to activate the relevant serine proteases) in the presence
of a cell-permeable, active-site-directed, fluorescently
labeled TPCK-derivative (FAM-FFCK), aiming to affinity-
label only the subset of serine proteases that are activated
during TNF-induced necroptosis. Lysates from the cells
were separated by two-dimensional (2D) gel electropho-
resis, and labeled protein spots were analyzed by mass
spectrometry. Out of the analyzed 128 protein spots, 80
could be identified with high (“confirmed”) and 28 with
lesser confidence (“candidate”). However, showing the
limitations of this method and obviously due to a
nonspecific background binding of FAM-FFCK, most of
the 108 proteins turned out to be non-proteases. Never-
theless, the mitochondrial serine protease HtrA2/Omi was
identified in this screen with high confidence (Figure 2),
and we considered it as the most promising candidate,
because it had been already associated with both caspase-
dependent as well as caspase-independent PCD [25].
HtrA2/Omi mediates TNF-induced necroptosis
To investigate whether HtrA2/Omi was indeed function-
ally involved in the execution of TNF-induced ne-
croptosis, we performed a first set of experiments in
which we blocked the serine protease activity of HtrA2/
Omi with the specific inhibitor Ucf-101 [36]. As shown
in Figure 3A, treatment with Ucf-101 uniformly
protected L929Ts, HT-29 and Jurkat I42 (a FADD-
deficient, TNF-R2-transfected Jurkat subline which rapidly
undergoes necroptosis in response to TNF [37]) cells from
TNF-induced necroptosis, strongly suggesting that the
serine protease activity of HtrA2/Omi is required for this
process. Notably, incubation of L929Ts cells with Ucf-101
in combination with TPCK did not confer a stronger pro-
tection from necroptosis than the individual application of
each inhibitor (Figure 3B), suggesting that both inhibitors
do not act in an additive manner but rather via the same
signaling pathway or even the same target (i.e. HtrA2/
Omi). However, since results obtained with pharmaco-
logical inhibitors should be interpreted with a certain cau-
tion due to their potential nonspecific effects, we sought
to further substantiate the function of HtrA2/Omi in
TNF-induced necroptosis by selectively targeting its ex-
pression using RNA interference. As shown in Figure 3C,
transfection of murine L929Ts or human Jurkat I42 cells
with the corresponding siRNAs clearly downregulated the
expression of HtrA2/Omi (although not completely).
However, we did not detect a corresponding inhibition of
TNF-induced necroptosis; i.e. loss of intracellular ATP
measured as a marker for cell death was not prevented by
HtrA2/Omi-specific siRNAs relative to a negative control
Figure 1 Inhibition of serine proteases, but not metalloproteases, cathepsin or calpain/cysteine proteases protects from TNF-induced
necroptosis. A. Cells were stimulated or not with 100 ng/ml TNF for 5 (L929Ts), 16 (NIH3T3, HT-29), or 20 h (Jurkat) with optional addition of 20
(L929Ts, NIH3T3, HT-29) or 50 μM (Jurkat) of the broad-spectrum caspase inhibitor zVAD-fmk to prevent apoptosis, 2 (Jurkat) or 5 μg/ml (HT-29)
cycloheximide (CHX) to sensitize for necroptosis [14] and 50 (L929Ts, NIH3T3) and 25 μM (Jurkat, HT-29) TPCK, or 50 μM of the necroptosis
inhibitor necrostatin-1 (Nec-1, to confirm necroptosis). Subsequently, the cells were analyzed for loss of membrane integrity as a marker for cell
death by PI staining and flow cytometry. Asterisks indicate statistical significance (t-test), *p < 0.05, **p < 0.01, ***p < 0.001. Micrographs show the
morphology of untreated vs. necroptotic vs. L929Ts cells protected by TPCK. Scale bar: 100 μm. B. L929Ts and NIH3T3 cells were preincubated for
2 h with TAPI-1, GM 6001 and marimastat and subsequent addition of TNF/zVAD as in A before cell death was analyzed. C. L929Ts cells were
incubated with TNF/zVAD as in A with optional addition of 20 μM zFA-fmk, CA-074 Me, E-64 or (in a separate experiment) zFF-fmk before cell
death was analyzed. For all flow cytometric analyses of membrane integrity, we measured the percentage out of a total of 10,000 analyzed cells
that show loss of membrane integrity (this is calculated as 100% minus the percentage of intact, large PI-negative cells to account for
disintegrated dead cells that have lost their PI staining again due to diffusion). For all figures, representative data from one out of at least two or
more experiments are shown and error bars indicate the standard deviations (SD) from at least triplicate determinations.
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result, the achieved reduction of HtrA2/Omi expression
(and thus activity) might not yet be sufficient to inhibit
the death response. Alternatively, this result might indi-
cate lack of a role for HtrA2/Omi in TNF-induced
necroptosis and leave the possibility that cell death ismediated by TPCK-sensitive serine proteases other than
HtrA2/Omi. Regardless of either interpretation, these
results were not consistent with the data obtained by
pharmacological inhibition with Ucf-101. To resolve this
discrepancy, we obtained and analyzed mouse embryonic
fibroblasts (MEF) from HtrA2/Omi-deficient mice in a
Figure 2 Identification of HtrA2/Omi as a candidate serine protease involved in necroptosis. L929Ts cells were stimulated with 100 ng/ml
TNF for 5 h in combination with 20 μM zVAD-fmk, 2 μg/ml CHX (to enhance necroptosis) and 50 μM FAM-FFCK. Subsequently, lysates from the
cells were separated by 2D gel electrophoresis and analyzed for protein spots labeled by FAM-FFCK (left panel, green), or for the total of all
separated protein spots by staining with Flamingo Pink (right panel, red). The protein spot subsequently identified by mass spectrometry as
HtrA2/Omi is indicated by arrows.
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and as shown in Figure 3D, these cells are completely
devoid of any residual HtrA2/Omi protein (and thus acti-
vity). In assays for TNF-induced necroptosis, HtrA2/Omi-
deficient cells were fully protected (Figure 3D), confirming
the results with Ucf-101 and in summary validating that
HtrA2/Omi is a key mediator of TNF-induced necroptosis.
HtrA2/Omi induces monoubiquitination rather than
cleavage of its substrate UCH-L1 during TNF-induced
necroptosis
The above results demonstrated that the protease acti-
vity of HtrA2/Omi is required for the necroptotic re-
sponse to TNF, suggesting that necroptosis is relayed by
proteolysis of HtrA2/Omi substrates. Since a previous
study had shown that UCH-L1 is cleaved by HtrA2/Omi
during staurosporine-induced apoptosis [38], we investi-
gated whether UCH-L1 also served as a substrate and
thus potential downstream effector of HtrA2/Omi in
TNF-induced necroptosis. Initially supporting this as-
sumption, Western blots revealed a decrease of the
25-kDa band representing full-length UCH-L in lysates
from wild-type (WT) MEF after induction of necroptosis
by TNF/zVAD/CHX (but not in untreated or zVAD/
CHX-treated controls, Figure 4A). Moreover, this de-
crease was not detectable in HtrA2/Omi-deficient MEF
(Figure 4A), and is therefore caused by HtrA2/Omi in
the course of necroptosis. In addition, HtrA2/Omi-
deficient MEF showed higher basal levels of UCH-L1
(Figure 4A), suggesting a constitutive negative impact of
HtrA2/Omi on the levels of UCH-L1 in WT MEF. Since
the monoclonal UCH-L1 antibody utilized in this experi-
ment recognized only the full-length 25-kDa form of
UCH-L1, we incubated a parallel blot with a polyclonalantibody for UCH-L1 to visualize additional cleavage
fragments. As shown in Figure 4A, this antibody indeed
detected a smaller band at 15 kDa. However, this band
was uniformly present in WT and HtrA2/Omi-deficient
MEF. Moreover, it did not increase but rather decreased
upon induction of necroptosis in WT MEF (showing the
same intensity pattern as full-length UCH-L1). There-
fore, the 15-kDa band most likely represents a cleavage
fragment of UCH-L1 which is constitutively generated
by a protease distinct from HtrA2/Omi, and indepen-
dent from necroptosis.
Park and colleagues have reported that HtrA2/Omi
cleaves UCH-L1 during staurosporine-induced apop-
tosis, generating a 10-kDa cleavage fragment (although
this was shown only in vitro and upon overexpression,
but not for the endogenous proteins) [38]. We therefore
included positive controls for cleavage of endogenous
UCH-L1 by endogenous HtrA2/Omi by treating WT
MEF with staurosporine, and additionally compared
them to staurosporine-treated HtrA2/Omi-deficient MEF.
Furthermore, we employed gel systems that specifically
resolve low molecular weight fragments to detect any
cleavage fragments that might have been missed in the ex-
periment shown in Figure 4A. In line with the observa-
tions by Park and colleagues (but now shown for the first
time for endogenous UCH-L1), we detected a very faint
UCH-L1 cleavage fragment of 10 kDa in lysates from
staurosporine-treated WT MEF. As an explanation for the
low intensity of the 10-kDa fragment, Park and colleagues
had previously been unable to detect endogenous cleavage
fragments in WT MEF altogether (only in vitro and in
overexpression systems), and had attributed this to an
enhanced susceptibility of these fragments to degradation
[38]. Nevertheless, the presence of this fragment in
Figure 3 HtrA2/Omi mediates TNF-induced necroptosis. A. Cells were left without, or pretreated for 2 h with 25 (Jurkat I42) or 50 μM
(L929Ts, HT-29) of Ucf-101. Subsequently, cells were further incubated for 5 (L929Ts), 16 (HT-29) or 6 h (Jurkat I42) without or with addition of
100 ng/ml TNF, 20 (L929Ts, HT-29) or 50 μM (Jurkat I42) zVAD-fmk and 5 μg/ml CHX (HT-29) before cell death was analyzed. ***p < 0.001.
Micrographs show the morphology of untreated vs. necroptotic cells vs. L929Ts cells protected by Ucf-101. Scale bar: 100 μm. B. L929Ts cells
were left untreated or treated with TNF/zVAD with or without Ucf-101 as in A with addition of 50 μM TPCK or not and analyzed as in
A. C. Cells were transfected with siRNAs specific for murine (L929Ts) or human HtrA2/Omi (Jurkat I42), or a negative control siRNA (siCtr). After 48
or 72 h, cells were treated with 100 ng/ml TNF and 20 (L929Ts) or 50 μM (Jurkat I42) zVAD-fmk for another 5 (L929Ts) or 6 h (Jurkat I42) before
the decrease of intracellular ATP levels was determined as a marker for cell death. Control Western blots of transfected but untreated cells were
performed to verify downregulation of endogenous murine or human HtrA2/Omi. Detection of actin served as a loading control. D. Upper panel:
wild-type (WT) and HtrA2/Omi-deficient MEF were stimulated with 100 ng/ml TNF, 20 μM zVAD-fmk and 1 μg/ml CHX for 16 h before cell death
was determined. ***p < 0.001. Control Western blots show the presence or absence of murine HtrA2/Omi. Detection of actin served as a loading
control. Lower panel: micrographs show the morphology of untreated and TNF/zVAD/CHX-treated WT vs. HtrA2/Omi-deficient MEF.
Scale bar: 100 μm.
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Figure 4 HtrA2/Omi induces monoubiquitination rather than cleavage of its substrate UCH-L1 during TNF-induced necroptosis.
A. Wild-type (WT) and HtrA2/Omi-deficient MEF were left untreated or stimulated for 16 h with 20 μM zVAD-fmk and 1 μg/ml CHX in the
presence (to induce necroptosis) or absence (for control) of 100 ng/ml TNF before UCH-L1 was detected with a monoclonal antibody that
recognizes the full-length 25-kDa form of UCH-L1 (mAB UCH-L1) or, on a parallel blot, with a polyclonal antibody to detect all cleavage fragments
of UCH-L1 (pAb UCH-L1). An asterisk marks the 35-kDa band corresponding to the predicted size of monoubiquitinated UCH-L1. B. WT and
HtrA2/Omi-deficient MEF were stimulated as in A, and additionally with 0.5 μM staurosporine for 8 h. Lysates were separated on 10–20% w/v
Tris-Tricine gels (Biorad) to resolve low molecular weight proteins and immunoblotted with pAb UCH-L1. The blot was deliberately overexposed
to visualize faint cleavage fragments. The 10-kDa UCH-L1 cleavage fragment generated by HtrA2/Omi during staurosporine-induced apoptosis is
indicated (arrow, red box). C. WT and HtrA2/Omi-deficient MEF were treated with TNF/zVAD/CHX as in A for the indicated times and analyzed for
proteins reactive with pAb UCH-L1 by Western blot. An asterisk marks the appearance of the 35-kDa band identical to the predicted size of
monoubiquitinated UCH-L1. D. Lysates from WT and HtrA2/Omi-deficient MEF were incubated with 20 μM of an HA-tagged ubiquitin-derived
probe (HAUbVME) in 50 mM Tris, 150 mM NaCl, pH 8.0 for 90 min at 37°C and subsequently analyzed by immunoblotting with HA antibody and
reanalyzed with pAB UCH-L1. In panels A-D, detection of actin served as a loading control. E. An immunoprecipitation was performed using
lysates from necroptotic WT MEF (treated with TNF/zVAD/CHX as in A) and an antibody for ubiquitin. Subsequently, UCH-L1 was detected by
Western blot using pAb UCH-L1.
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cient MEF (Figure 4B) confirmed that UCH-L1 is cleaved
by HtrA2/Omi in staurosporine-induced apoptosis. In
contrast, the 10-kDa fragment was clearly absent in alllysates from both WTand HtrA2/Omi-deficient MEF ana-
lyzed for TNF-induced necroptosis as well as the accom-
panying controls (Figure 4B). Given these results, we
considered it unlikely that the observed decrease of the
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MEF was resulting from a direct proteolytic cleavage of
UCH-L1 by HtrA2/Omi.
Searching for an alternative explanation, we noticed that
the disappearance of the 25-kDa UCH-L1 band during
TNF-induced necroptosis was accompanied by the con-
current appearance of a prominent band of ~35 kDa
(Figure 4A). Like the 25-kDa band, this band was com-
pletely absent in HtrA2/Omi-deficient as well as in un-
treated WT MEF (and only very faintly detectable as a
background band in control WT MEF treated with
zVAD/CHX). To obtain further insight, we extended the
above analysis in a timecourse experiment. As shown in
Figure 4C, induction of necroptosis in WT MEF by TNF/
zVAD/CHX caused the appearance of the ~35-kDa band
within 4 h of treatment and again reduced the levels of
the 25-kDa UCH-L1 form (most clearly visible after 8 h).
Again, this was not detectable in HtrA2/Omi-deficient
MEF (Figure 4C), in line with the results shown in
Figure 4A, and once more demonstrating that these
changes are mediated by HtrA2/Omi. Interestingly, a band
of ~35 kDa reactive with UCH-L1 antibodies has also
been described by other groups, and has been suggested
to represent a monoubiquitinated form of UCH-L1
[29,32,39]. To clarify whether this was the case, we incu-
bated lysates from WT and HtrA2/Omi-deficient MEF
with an ubiquitin-derived probe tagged to hemagglutinin
(HA) that covalently binds to deubiquitinating enzymes
such as UCH-L1 [32]. In Western blots for UCH-L1, incu-
bation of the lysates with this probe caused a shift of the
full-length UCH-L1 band from 25 kDa to ~35 kDa. More-
over, an antibody against the HA tag of the probe selec-
tively reacted with this ~35-kDa band (Figure 4D). We
additionally immunoprecipitated ubiquitinated proteins
from WT MEF after induction of necroptosis with TNF/
zVAD/CHX and performed Western blots for UCH-L1,
again detecting a band at ~35 kDa (Figure 4E). In sum-
mary, these results confirm that the size shift from 25 kDa
to ~35 kDa is indeed caused by monoubiquitination of
UCH-L1. It is noteworthy that two of the above groups
have independently shown that this modification leads to
activation of UCH-L1 [29,32], prompting us to investigate
the functional relevance of UCH-L1 activity for TNF-
mediated necroptosis in the next set of experiments.
Inhibition of UCH-L1 protects from TNF-induced
necroptosis
For this purpose, we employed LDN57444, a previously
described active site-directed inhibitor which specific-
ally targets the enzymatic activity of UCH-L1 [40]. As
shown in Figure 5A, treatment of L929Ts cells with
LDN57444 significantly protected from TNF-mediated
necroptosis. To exclude that this was due to nonspecific
effects of this pharmacological inhibitor, we additionallydownregulated UCH-L1 by RNA interference, measur-
ing loss of intracellular ATP as a marker for TNF/
zVAD-induced necroptosis. Compared to L929Ts cells
transfected with a negative control siRNA, transfection
with an siRNA specific for UCH-L1 significantly in-
hibited loss of ATP, almost as effective as transfection
with an siRNA specific for RIPK3, which we used as a
positive control to validate the assay (Figure 5B). In
summary, the above results support the hypothesis that
UCH-L1 is not cleaved by, but rather indirectly acti-
vated downstream of HtrA2/Omi, further relaying the
necroptotic signals elicited by TNF.
UCH-L1 is a mediator of caspase-independent,
non-apoptotic cell death in diseased kidney podocytes
Remarkably, UCH-L1 has also been associated with
increased cell death in patients with kidney failure. In
particular, de novo expression and thus increased UCH-
L1 activity in kidney podocytes was found in specific,
mostly irreversible forms of glomerular injury in pa-
tients, rats and mice and is apparently responsible for
disease aggravation in experimental models of mem-
branous nephropathy [30,31]. Accordingly, inhibition of
UCH-L1 with LDN57444 diminished kidney damage in
these models whereas overexpression of UCH-L1 en-
hanced podocyte destruction. At present, it is however
completely unclear whether death of podocytes in re-
sponse to increased UCH-L1 activity is mediated by
apoptosis, by autophagic mechanisms, by necroptosis or
other forms of programmed necrosis. For apoptosis, evi-
dence for podocyte death is scarce, suggesting that apop-
tosis is not a general pathway of podocyte loss in vivo
[41]. As a second potential mode of PCD, autophagy has
rather been associated with a healthy and differentiated
status of podocytes, implicating that podocyte autophagy
is a protective instead of pro-death pathway in glome-
rular disease [41]. Finally, necroptosis in podocytes has
been investigated so far in only one study, where healthy
podocytes (which do not express UCH-L1 [28]) proved
resistant to both necroptosis and apoptosis [42].
To explore the mode of cell death that podocytes
undergo in response to an increase in UCH-L1 ex-
pression/activity, we utilized murine podocytes stably
transduced with a doxycycline-inducible overexpression
construct for UCH-L1 (UCH-L1 tet-on podocytes). In a
first approach, we investigated cell death in untreated and
doxycycline-treated UCH-L1 tet-on podocytes directly. As
shown in Figure 6A, cell death in untreated UCH-L1
tet-on podocytes was negligible whereas induction of
UCH-L1 expression by doxycycline significantly increased
the numbers of dying podocytes (thereby also demonstrat-
ing the functionality of the system). More importantly, the
addition of zVAD-fmk as a broad-spectrum inhibitor of
caspases and thus of apoptosis did not inhibit but rather
Figure 5 Inhibition of UCH-L1 protects from TNF-induced necroptosis. A. L929Ts cells were prestimulated for 3 h with 50 μM of the UCH-L1
inhibitor LDN57444 or left unstimulated before addition of 100 ng/ml TNF and 20 μM zVAD-fmk for 5 h. Subsequently, cell death was analyzed
by PI staining and flow cytometry. Asterisks indicate statistical significance (t-test), ***p < 0.001. Micrographs additionally show the morphology of
untreated L929Ts cells vs. necroptotic cells vs. cells protected by LDN57444. Scale bar: 100 μm. B. L929Ts cells were transfected with an siRNA
that does not elicit an RNAi response (negative control, siCtr), with an siRNA specific for murine UCH-L1, and with an siRNA specific for murine
RIPK3 (positive control for protection from necroptosis, siRIPK3) as described in “Methods.” 48 h after transfection, cells were treated with
100 ng/ml TNF and 20 μM zVAD-fmk for another 5 h before the decrease of intracellular ATP levels was determined as a marker for cell death.
ATP levels are shown relative to controls that were not treated with TNF/zVAD. Asterisks indicate statistical significance (t-test), **p < 0.01,
***p < 0.001.
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have previously observed this effect of zVAD-fmk in
necroptosis [14,33,43], excluding that de novo expression
and thus increased UCH-L1 activity causes death of
podocytes by apoptosis but rather pointing to pro-
grammed necrosis/necroptosis as the responsible suicide
program.
To extend these results, we investigated cleavage of
PARP-1, a DNA-associating repair enzyme which is
inactivated in apoptosis by caspase-3-dependent proces-
sing of the mature 116-kDa protein to an 89-kDa clea-
vage product [44]. When we analyzed lysates from
UCH-L1 tet-on podocytes treated with doxycycline for
72 h or not in Western blots, the full-length 116-kDa
PARP-1 band was uniformly visible in all samples, to-
gether with a pattern of additional bands. However, this
pattern did not change upon treatment with doxycycline
(Figure 6B). In particular, the characteristic disappea-
rance of the full-length 116-kDa PARP-1 band as well as
the corresponding increase of the 89-kDa cleavage frag-
ment that we have previously observed for apoptosis inmultiple studies [13,15,33], and which is also shown for
control in L929Ts cells (Figure 6B) could not be de-
tected. Given that caspase-3 acts downstream of all
other apoptotic caspases as the central effector caspase
of both extrinsic and intrinsic apoptosis, these results
provided a second line of evidence that caspase activa-
tion and thus apoptosis seems not to occur during
UCH-L1-mediated death of kidney podocytes.
To address this point in more detail, we directly mea-
sured the activity of caspase-3 and caspase-8 (as the major
initiator caspase activated by death receptors). As shown
in Figure 6C, no increase in caspase-3 or caspase-8 activity
beyond the already present basal levels was detectable in
doxycycline-treated (i.e. UCH-L1-overexpressing, Western
Blot in Figure 6C) vs. untreated UCH-L1 tet-on podocytes
or vs. negative controls (doxycycline-treated podocytes
that are stably transduced with empty vector; tet-
podocytes). In contrast, the activity of both caspases
was clearly increased in positive control lysates from
doxycycline-treated tet- podocytes treated with cyto-
chrome c and dATP to validate the assay, in summary
Figure 6 (See legend on next page.)
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Figure 6 UCH-L1 as a mediator of caspase-independent, non-apoptotic cell death in diseased kidney podocytes. A. UCH-L1 tet-on
podocytes were treated with 20 ng/ml doxycycline for 72 hours (+Dox) or not (−Dox) and 50 μM zVAD-fmk or no inhibitor. Cell death was
measured by trypan blue staining. ***p < 0.001. B. UCH-L1 tet-on podocytes were left untreated (−) or treated with doxycycline as in A (+) before
PARP-1-reactive bands were detected by immunoblotting. Cell lysates from untreated and apoptotic L929Ts cells (Co, treated with 100 ng/ml TNF
and 2 μg/ml CHX for 1 h) are shown as controls. Full-length and cleaved PARP-1 is marked by arrows. Detection of actin served as a loading
control. C. Aliquots from the stimulations in B were also analyzed for caspase activity. As negative control, tet- podocytes were treated with
doxycycline as in A; as positive control, lysates from doxycyline-treated tet- podocytes were incubated with cytochrome c and dATP to activate
caspases. Subsequently, the activity of caspases-3 and -8 was determined by measuring the cleavage of fluorogenic substrates (zIETD-afc and
zDEVD-afc) over 70 minutes. The Western blot below shows that UCH-L1 is indeed upregulated in doxycycline-treated but not untreated UCH-L1
tet-on podocytes and also not in doxycycline-treated negative control tet- podocytes. Treatment with doxycycline was performed as in
A. UCH-L1 was detected with mAb UCH-L1, detection of actin served as a loading control. D. Cell death was induced in UCH-L1 tet-on podocytes
by treatment with doxycycline as in A in the presence of 50 μM zVAD-fmk (+zVAD-fmk, middle and lower micrographs) or no inhibitor
(upper micrographs). Micrographs show the morphology of dying cells within a monolayer of healthy cells (overlay, nuclei are stained blue), and
in parallel the nuclear morphology of the same cells after staining with Hoechst dye (Hoechst). Original magnification: x 400.
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diated death of podocytes occurs without activation of
caspases and thus in a non-apoptotic manner.
Finally, when analyzed by microscopy, doxycycline-
treated UCH-L1 tet-on podocytes did not display typical
apoptotic changes such as membrane blebbing, type 2
chromatin condensation and accumulation of frag-
mented chromatin at the nuclear periphery which we
had earlier observed for apoptosis in other cell systems
[33]. Rather, only an incomplete, lumpy condensation of
chromatin was detectable that has previously been as-
sociated with programmed necrosis/necroptosis rather
than apoptosis [16]. Moreover, and as shown above for
cell death, the addition of zVAD-fmk did not affect the
changes in the cellular and nuclear morphology of
podocytes caused by doxycycline-induced overexpression
of UCH-L1 (Figure 6D). Altogether, these results rule
out caspase-dependent apoptosis but rather favor caspase-
independent, non-apoptotic forms of cell death such as
programmed necrosis or necroptosis as the most probable
cause for UCH-L1-mediated podocyte death.
Inhibition of UCH-L1 protects podocytes from
TNF-induced necroptosis
As a central proinflammatory cytokine, TNF may also
contribute to inflammatory reactions in the kidney and
thus to subsequent podocyte injury. We therefore
wanted to determine whether UCH-L1 can act as a me-
diator of TNF-induced necroptosis not only in L929Ts
cells (as shown in Figure 5), but also in podocytes. For
this purpose, we analyzed podocytes stably transfected
with an shRNA construct that causes permanent knock-
down of UCH-L1 or with a scrambled negative control
shRNA [30]. As shown in Figure 7, podocytes with stable
downregulation of UCH-L1 were significantly protected
from TNF-induced cell death when compared to control
podocytes. Moreover, and identical to podocyte death
caused by UCH-L1 overexpression (Figure 6A), theaddition of zVAD-fmk did not prevent TNF-induced cell
death, demonstrating that TNF indeed elicits necroptosis
in podocytes, and that UCH-L1 represents a down-
stream mediator of the necroptotic signaling cascade of
TNF also in podocytes.
Discussion
The impact of caspase-independent, non-apoptotic PCD
such as necroptosis/programmed necrosis has become in-
creasingly clear in the last years. This is particularly true
for pathological processes, for example renal [42], cardiac
and retinal ischemia/reperfusion injury, hyperacute shock
[45], brain damage or pancreatitis [12], Huntington’s,
Parkinson’s and Alzheimer’s disease, epilepsy, muscular
dystrophy, as well as for the destruction of cells by patho-
gens such as vaccinia virus, HIV, Shigella and Salmonella
[2,12,46,47]. The option to therapeutically interfere with
necroptosis/programmed necrosis has raised great ex-
pectations [12]. In consequence, a better knowledge of the
still incompletely understood signaling pathways and
the associated components will facilitate future stra-
tegies to interfere with damage induced by necroptosis/
programmed necrosis (e.g. in shock, stroke, myocardial
infarction or kidney failure). Here, we have identified
the proteases HtrA2/Omi and UCH-L1 as two such
components of TNF-induced necroptosis, and thus re-
vealed two novel targets for therapeutic intervention,
e.g. by future Ucf-101- or LDN57444-derived drugs
suited for use in patients.
Based upon the results of our study, we propose the
model shown in Figure 8 to integrate HtrA2/Omi and
UCH-L1 into the known signaling pathways of TNF-
induced necroptosis. In this model, binding of TNF to
TNF-R1 induces activation of the kinases RIPK1, RIPK3,
and of MLKL as components of the necrosomal core
complex. Notably, we have been unable to detect
HtrA2/Omi as part of the necroptotic TNF-R1 signaling
complex in preliminary experiments (D. A. and S. S.,
Figure 7 Inhibition of UCH-L1 protects podocytes from
TNF-induced necroptosis. Podocytes stably transfected with an
shRNA construct that causes permanent knockdown of UCH-L1
(shUCH-L1) or with a scrambled negative control shRNA (shCtr) were
treated with 100 ng/ml TNF in the presence of 50 μM zVAD-fmk or
vehicle for 3 h before loss of membrane integrity as a marker for cell
death was measured by trypan blue staining. Asterisks indicate
statistical significance (t-test), *p < 0.05. The Western blot below was
performed to demonstrate the permanent knockdown of UCH-L1 in
shUCH-L1 podocytes, but not in shCtr podocytes. UCH-L1 was
detected with mAb UCH-L1, detection of actin served as a loading
control. For each stable transfectant, lysates from four independent
flasks were analyzed.
Figure 8 HtrA2/Omi and UCH-L1 as novel components of
TNF-induced necroptosis. The scheme depicts the proposed roles
of HtrA2/Omi and UCH-L1 in TNF-induced necroptosis. Binding of
TNF to TNF-R1 triggers activation of the necrosomal core complex
consisting of RIPK1, RIPK3 and MLKL. Subsequently, the proteins
PGAM5L/S and Drp-1 form the mitochondrial attack complex,
resulting in the intramitochondrial activation of HtrA2/Omi.
Activated HtrA2/Omi then (by cleavage of yet unidentified
intramitochondrial substrates) indirectly causes monoubiquitination
and activation of UCH-L1, and finally, necroptosis. Accordingly,
inhibition of HtrA2/Omi (Ucf-101, knockout) or UCH-L1 (LDN57444,
siRNA) protects from necroptosis. Please see Discussion for
further details.
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reported an association of HtrA2/Omi with components
of the TNF-R1 signaling complex during necroptosis.
This is also consistent with reports showing that, in con-
trast to apoptosis, HtrA2/Omi is not released from mito-
chondria during TNF-induced necroptosis [23,48]. In
summary, these findings argue against a direct inter-
action of HtrA2/Omi with RIPK1, RIPK3 or MLKL but
instead suggest that HtrA2/Omi is activated indirectly
within the mitochondria. As the most likely mechanism,
MLKL has been found to activate the phosphatases
PGAM5L/S, which in turn couple to the mitochondrial
protein Drp-1, and as a mitochondrial attack complex
[11], may cause the subsequent intramitochondrial
activation of HtrA2/Omi. Consistent with a function of
HtrA2/Omi in TNF-induced necroptosis despite thisintramitochondrial localization, inhibition of HtrA2/Omi
activity by Ucf-101 or by genetic deletion (knockout)
blocks the necroptotic signal of TNF (this was similarly
observed for Ucf-101 in an independent study in neutro-
phils, where the authors also concluded that HtrA2/Omi
mediates necroptosis through its serine protease proper-
ties from within the mitochondria [48]). Downstream of
HtrA2/Omi, our data identify UCH-L1 as another, novel
component of the signaling cascade. In contrast to
staurosporine-induced apoptosis, where HtrA2/Omi
translocates into the cytosol and directly cleaves and
thus inactivates UCH-L1 [38], the intramitochondrial
localization of HtrA2/Omi during TNF-induced
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teins. Rather, and also explaining why we did not see a
direct cleavage (and thus inactivation) of UCH-L1 by
HtrA2/Omi, HtrA2/Omi seems to act indirectly, by yet
unknown mechanism (e.g. cleavage of unidentified in-
tramitochondrial substrates), causing the monoubiqui-
tination and activation of UCH-L1, finally resulting in
necroptosis (which can accordingly be blocked via
LDN57444 or by RNA interference).
As a side note, UCH-L1 belongs to the family of cyst-
eine proteases, and we wondered why the broad-spectrum
calpain/cysteine protease inhibitor E-64 did not confer
any significant protection from TNF-induced necroptosis
in the experiments performed in this study (Figure 1C) or
in additional control experiments (D. A., J. S. and S. V.,
unpublished observations). To the best of our knowledge,
inhibition of UCH-L1 by E-64 has also not been shown in
any other study. As a possible explanation, UCH-L1 is an
“atypical” cysteine protease because its active site is
misaligned when compared to productive cysteine pro-
teases [29]. Therefore, a general cysteine protease inhibi-
tor such as E-64 may have only limited impact on the
activity of UCH-L1, in contrast to a specific inhibitor such
as LDN57444 or to inhibition of UCH-L1 by RNA inter-
ference (which clearly protected L929Ts cells or podocytes
from TNF-induced necroptosis, Figure 5A-B, Figure 7).
We would also like to point out that HtrA2/Omi and
UCH-L1 obviously represent important, but most cer-
tainly not the only factors transmitting the necroptotic
death signals of TNF downstream of RIPK1/RIPK3/
MLKL. Whereas HtrA2/Omi is expressed ubiquitously
[23], the expression of UCH-L1 is restricted to certain
tissues [28,30]. Therefore, in tissues that do not express
UCH-L1, necroptosis must be relayed by additional, in-
dependent factors. Notably, the brain is an organ where
a rapid and efficient apoptotic elimination of cells is
dangerous, and where alternative, caspase-independent
forms of PCD predominate [16]. The brain is also the
organ with the highest expression of UCH-L1 in the
entire body [32], suggesting that a deregulation of UCH-
L1 activity in the brain may contribute to necroptotic
damage, e.g. after traumatic injury [31] or after stroke
(i.e. ischemia/reperfusion damage). Interestingly, both
UCH-L1 as well as HtrA2/Omi have been associated
with Parkinson’s disease, although a connection to
necroptosis has not been investigated so far. Moreover,
recent studies have found that necroptosis is also the
predominant damage mechanism in ischemia/reper-
fusion damage in the kidney [42,49], in summary indi-
cating that both brain and kidney are organs where
therapeutic strategies aiming to interfere with the
necroptotic actions of HtrA2/Omi and UCH-L1 may be
worthwhile options to consider for the future, e.g. with
regard to stroke or kidney failure.Conclusions
We have identified the proteases HtrA2/Omi and UCH-L1
as two crucial components of TNF-induced necroptosis,
and thus provided evidence that proteolysis is not only
critical for the regulation and execution of apoptosis, but
also essential for caspase-independent forms of PCD. A
model that integrates HtrA2/Omi and UCH-L1 into the
known signaling cascades of TNF-mediated necroptosis is
shown in Figure 8. With HtrA2/Omi and UCH-L1, we
have also revealed two novel targets for therapeutic inter-
vention, which may assist in developing strategies for the
treatment of damage induced by necroptosis/programmed
necrosis (e.g. in organs such as the kidney and the brain,
caused by stroke or kidney failure).
Methods
Reagents
Highly purified human recombinant TNF was provided by
BASF Bioresearch (Ludwigshafen, Germany). Benzylo-
xycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (zVAD)
was from Bachem (Bubendorf, Switzerland). TPCK, ma-
rimastat, benzyloxycarbonyl-Phe-Ala-fluoromethylketone
(zFA-fmk) and trans-Epoxysuccinyl-L-leucylamido(4-gua-
nidino)butane (E-64), were purchased from Sigma
(Deisenhofen, Germany), necrostatin-1, TAPI-1, GM6001,
5-[5-(2-nitrophenyl)furfurylidine]-1,3-diphenyl-2-thiobarbi-
turic acid (Ucf-101), benzyloxycarbonyl-Phe-Phe-fluoro-
methylketone (zFF-fmk) and LDN57444 from Merck
Millipore (Darmstadt, Germany), and N-[L-3-trans-(pro-
pylcarbamoyl)-oxirane-2-carbonyl]-L-Ile-L-Pro methyl ester
(CA-074 Me) from Biomol (Hamburg, Germany). Car-
boxyfluorescein-labeled phenylalanine chloromethyl ketone
(FAM-FFCK) was from Immuno Chemistry Technologies
(Bloomington, MN, USA). Staurosporine was obtained
from Selleckchem (Munich, Germany), Ubiquitin vinyl me-
thyl ester, HA-tag (HaUbVME) from Enzo Life Sciences
(Lausen, Switzerland).
Cell culture
L929Ts is a TRAIL-sensitive L929 subline derived in our
laboratory [33]. NIH3T3 cells naturally expressing RIPK3
and therefore sensitive to necroptosis have been pre-
viously described [15,50,51]. Jurkat and HT-29 cells were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Jurkat I42 cells were a kind
gift from Francis Ka-Ming Chan (Worcester, MA, USA).
Immortalized MEF deficient for HtrA2/Omi [24] and their
WT counterparts were originally generated by Julian
Downward (London, U. K.) and kindly provided by
Thomas Langer (Cologne, Germany). Cells were culti-
vated in DMEM (NIH3T3, MEF), or a mixture of Click’s/
RPMI 1640 medium (all other cell lines) supplemented
with 10% v/v fetal calf serum and 2 mM glutamine at 37°C
in a humidified incubator containing 5% w/v CO2. Media
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vate (HT-29) and 50 μg/ml each of streptomycin and peni-
cillin. Murine podocytes (a kind gift from K. H. Endlich,
Greifswald) were cultured as described [52]. For differenti-
ation, podocytes were cultured for 14 days under non-
permissive conditions (37°C, 7.4% w/v CO2, RPMI 1640
supplemented with 10% v/v fetal calf serum, 10 mM N-2-
hydroxyethylpiperazine-N0-2-ethanesulfonic acid, 1 mM
sodium pyruvate, 100 U/ml penicillin, 100 mg/ml
streptomycin).
Flow cytometric analysis of membrane integrity
Cells were seeded in twelve-well plates at 5 x 104 cells/
well. Following treatment, both detached and adherent
cells were collected by centrifugation. The cells were
resuspended in PBS/5 mM EDTA containing 2 μg/ml
propidium iodide (PI), and the red fluorescence was
measured on a FACSCalibur flow cytometer (Becton
Dickinson).
Statistical analysis
p values were calculated using Student’s t-test. Statistical
significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001.
Microscopy
For documentation of cell morphology, images from
unfixed cells were obtained using an Axiovert 10 micro-
scope (Zeiss, Oberkochen, Germany) and a DS-5M-L1
digital sight camera system (Nikon, Düsseldorf, Germany).
2D gel electrophoresis, image analysis and spot picking
The two-dimensional gel electrophoresis was essentially
performed as described before [53]. After harvesting, cells
were lysed on ice for 10 min in TNE buffer (50 mM Tris
pH 8.0, 1% v/v NP40, 2 mM EDTA) containing 10 μg/ml
protease inhibitor cocktail (Roche, Mannheim, Germany).
For protein precipitation, trichloroacetic acid (TCA) was
added to the protein lysate to a final concentration of
10% v/v . The mixture was incubated for 30 min on ice
and centrifuged at 10,000 × g at 4°C for 20 min. The
supernatant was removed, ice-cold acetone was added to
wash the pellet and the sample was centrifuged as above.
After removal of the supernatant, the pellet was air dried
and resuspended in lysis buffer (pH 8.5) containing 7 M
urea, 2 M thiourea, 30 mM Tris, 4% w/v CHAPS. The
supernatant containing the solubilized proteins was reco-
vered after centrifugation for 20 min at 20,000 × g at 4°C.
A total amount of 250 μg of protein was mixed with re-
hydration buffer (7 M urea, 2 M thiourea, 4% w/v
CHAPS, 2% v/v immobilized pH gradient (IPG) buffer
pH 3–11 and 2% w/v DTT) and applied by cup-loading
onto 24 cm non-linear pH 3–11 IPG gel strips for
isoelectric focusing (IEF). The second dimension was
performed on 26 × 20 cm large 12.5% w/v gels afterreduction and alkylation using the Ettan DALTsix large
vertical electrophoresis system from GE Healthcare
(Munich, Germany). The gels were removed from the glass
plates, mounted on a non-backed gel frame, and scanned
on a Typhoon Trio imager (GE Healthcare) at green fluo-
rescence. Subsequently, the gels were stained overnight
with Flamingo Pink (Bio-Rad, Munich, Germany), and
scanned again at red fluorescence. The obtained images
were analyzed using Image Master 6.0 (GE Healthcare).
Selected spots were picked with a 2 mm picking head. The
picked gels were again scanned to verify the correct loca-
tion of the punched spots.
In-gel tryptic digestion and mass spectrometry
The punched gel spots were sequentially washed with
water, with 50 mM ammonium bicarbonate (ABC) in
50% v/v MeOH, with 70% v/v acetonitrile (ACN), and
dehydrated in pure ACN. ACN was evaporated in a
SpeedVac centrifuge (ThermoFisher Scientific, Dreieich,
Germany), and the dry gel pieces were subjected to in-gel
digestion with 100 ng porcine sequencing-grade trypsin
(Serva, Heidelberg, Germany) in 25 mM ABC at 37°C
overnight. For peptide extraction, 20 μl of 0.1% v/v
trifluoroacetic acid (TFA) in ACN was added and the sam-
ples were sonicated for 15 min. The supernatants were re-
moved and the gel spots were again incubated with 20 μl
of 0.1% v/v TFA in ACN for 10 min. The supernatants of
both steps were combined, dried in a SpeedVac centrifuge,
redissolved in 0.8 μl MALDI matrix solution (3.2 mg/ml
α-cyanohydroxycinnamic acid (Sigma) in 65% v/v ACN/
0.1% v/v TFA), spotted onto 384-well stainless steel
MALDI plates and air-dried. Spectra were acquired on an
AB SCIEX MALDI-TOF/TOF 5800 (AB SCIEX, Darm-
stadt, Germany) mass spectrometer in positive ion mode.
For MS measurements, 2000 shots were accumulated in
the mass range of 800–4000 m/z. Default calibration was
performed using the 4700 Proteomics Analyzer Stan-
dards Kit, while MS measurements were calibrated in-
ternally using trypsin and contaminant peaks (842.509,
2211.105, 2225.120 and 2807.315 Da). Precursor selec-
tion for MS/MS analysis was achieved using the 4000
Series Explorer Software (AB SCIEX) with acquisition of
the 20 most intense precursors (S/N > 20), beginning
with the strongest first. All MS/MS spectra were ac-
quired with 1 KV collision energy at ambient air (CID
medium: 1.25 x 10–6 Torr) using 3000 laser shots. For
peptide identification, MALDI-TOF/TOF MS/MS raw
files were searched using ABSciex GPS software (Version
3.6, build 332) with the following pre-filter settings: only
peaks within a mass range from 60 Da to the precursor
mass minus 35 Da and S/N ratio above 10 were used.
Spectra were searched with Mascot (version 2.2.04, Matrix
Science, London, U.K) against the Swissprot database
using Mus musculus as a taxonomy filter (15 Feb 2011,
Sosna et al. Cell Communication and Signaling 2013, 11:76 Page 15 of 18
http://www.biosignaling.com/content/11/1/7616345 sequences) and the following parameters: precursor
tolerance, 50 ppm; MSMS tol, 0.3 Da; max missed cleav-
ages 2. Oxidation (M) was set as a variable modification,
while carbamidiomethylation (C) was set as a fixed modi-
fication. Proteins were considered identified when either 2
peptides were identified with a confidence interval ≥ 99%
(p < 0.01) or 3 peptides ≥ 95% (p < 0.05).
RNA interference
The validated siRNA specific for human HtrA2/Omi
(ID # s654), the predesigned siRNAs specific for murine
HtrA2/Omi (ID # s82292, s82292) murine UCH-L1
(ID # s75710), murine RIPK3 (ID # s80755) as well as
the negative control siRNA (ID # AM4611) were ob-
tained from Life Technologies, Darmstadt, Germany.
L929Ts cells were transfected with 150 pmol siRNA by
Amaxa nucleofection (Lonza, Cologne, Germany), using
solution V and program T-20. Jurkat I42 cells were
transfected with 30 pmol siRNA and HiPerFect transfec-
tion reagent (Qiagen, Hilden, Germany).
Measurement of intracellular ATP levels
The intracellular ATP content of cells was determined
with the Cell Titer Glo Assay Kit (Promega, Mannheim,
Germany) following the instructions of the manufacturer.
Immunoblots
Unless otherwise indicated, cells were harvested after
treatment and lysed at 4°C in TNE buffer containing
150 mM NaCl, 10 μg/ml protease inhibitor cocktail,
1 mM sodium orthovanadate and 5 mM NaF. Identical
amounts of cell protein per lane were resolved by electro-
phoresis on SDS polyacrylamide gels. After electrophor-
etic transfer to nitrocellulose, reactive proteins were
detected using antisera specific for actin (sc-1615, Santa
Cruz, Heidelberg, Germany; A1978, Sigma), HtrA2/Omi
(ab32092, Abcam, Cambridge, UK), UCH-L1 (rat mono-
clonal, clone U104, generated as outlined below, or rabbit
polyclonal, CL95101, Cedarlane, Burlington, Ontario,
Canada), HA (1187423, Roche), PARP-1 (9542, Cell
Signaling, Danvers, MA, USA) and the ECL detection kit
(GE Healthcare). Equal loading as well as efficiency of
transfer was routinely verified for all Western blots by
Ponceau S staining, and by reprobing the membranes for
actin.
Generation of monoclonal UCH-L1 antibodies
Wistar rats were initially immunized intraperitoneally
(i.p.) with 100 μg of purified UCH-L1 (kindly provided
by Gregory A. Petsko, Waltham, MA, USA) in 60 μl
phosphate buffer saline (PBS) emulsified with 40 μl of
Gerbu adjuvant MM (Gerbu Biotechnik, Heidelberg,
Germany). The rats were boosted i.p. on days 14 and 21
with 50 μg of purified protein emulsified with 20% v/v ofthe adjuvant. The last two doses (50 μg UCH-L1 in PBS)
were administered on days 28 and 29 without adjuvant,
while the fusion was done on day 30. Spleen cells from
immunized animals were collected and fused with
Ag8.653 myeloma cells using polyethylene glycol 1500
(Roche). The fused cells were cultured in selection
medium (HAT, Sigma) for 10 days and screened by
ELISA for anti-UCH-L1 antibodies. Hybridoma clones
producing anti-UCH-L1 monoclonal antibodies (mAbs)
were then cultivated in serum-free medium and the
mAbs were purified using protein G affinity chromato-
graphy (GE Healthcare). The isotype of the anti-UCH-L
(U104) clone (IgG1, λ) was determined by using ELISA
rat mAb isotyping kit (ThermoFisher).
Immunoprecipitations
Cellular lysates were precleared with GammaBind G-
sepharose (GE Healthcare) and immunoprecipitation was
performed over night on ice using anti-ubiquitin IgG1
monoclonal antibody (MAB1510, Merck Millipore, 1:100
dilution). After collection of the immunecomplexes with
GammaBind G-sepharose and three washing steps in lysis
buffer, the immunoprecipitated proteins were analyzed by
SDS-PAGE and Western blot.
Generation of stably transfected podocytes with inducible
overexpression or downregulation of UCH-L1
For inducible overexpression of UCH-L1, the Retro-X
Tet-On Advanced Inducible Expression System (Clontech,
Mountain View, CA, USA) was used according to the
manufacturers’ instructions. Briefly, wildtype murine
UCH-L1 was amplified by polymerase chain reaction from




quently cloned into the multiple cloning site of the
pRetroX-Tight-Pur vector using NotI and MluI (Thermo-
Fisher). The sequence of UCH-L1 was verified by sequen-
cing (Eurofins MWG Operon, Ebersberg, Germany). For
virus production, phoenix ecotropic packaging cells were
transfected using DNA/CaCl2 precipitation with the
pRetroX-Tet-On Advanced vector, with the pRetroX-
Tight-Pur-UCH-L1 vector or the pRetroX-TightPur empty
vector as a control, respectively. The virus-containing
supernatant of the pRetroX-Tet-On transfected phoenix
cells was transferred to a 10 cm plate containing podocyte
target cells at around 50% to 60% confluence; the infection
steps were repeated twice. Selection for integration of the
pRetroX-Tet-On Advanced expression plasmid was per-
formed with G418 (500 μg/ml, Life Technologies) for
7 days. Afterwards, the virus-containing supernatant of the
pRetroX-Tight-Pur-UCH-L1 transfected phoenix cells was
transferred to the pRetroX-Tet-On Advanced transduced
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repeated twice. Selection for integration of the pRetroX-
Tight-Pur-UCH-L1 plasmid was performed with pu-
romycin (1.5 μg/ml, Sigma). For negative control
experiments, the pRetroX-Tight-Pur vector was trans-
duced without insert (tet-) into the pRetroX-Tet-On
Advanced expressing podocytes. For induction of UCH-L1
overexpression, UCH-L1 tet-on or tet- podocytes were
cultured in the presence of tetracycline free medium (PAN-
Biotech, Aidenbach, Germany) supplemented with 20 ng/ml
doxycycline or without doxycycline for control. For stable
knockdown experiments, shRNA627 to murine UCH-L1
or scrambled shRNA for control was overexpressed in
podocytes as described before [30].Analysis of caspase activity, cell death, and cellular and
nuclear morphology in podocytes
105 differentiated UCH-L1 tet-on or tet- podocytes were
plated in 6-well plates in tetracycline-free RPMI 1640
medium (Life Technologies) supplemented with 10% v/v
fetal calf serum, 10 mM N-2-hydroxyethylpiperazine-N0-
2-ethanesulfonic acid, 1 mM sodium pyruvate, 100 U/ml
penicillin and 100 mg/ml streptomycin. UCH-L1 over-
expression was induced with 20 ng/ml doxycycline for
72 hours or not. For measurements of caspase activity,
cells were collected and lysed in a buffer containing
10 mM Hepes pH 7.4, 142 mM KCl, 5 mM MgCl2, 1 mM
EGTA, 0.2% v/v NP40, 1 mM DTT and 2 mM Pefabloc
(Roche). To generate positive controls, 20 μg of cells lysate
were equilibrated for 1 h at 30°C after the addition of
1 mM dATP and 10 μM cytochrome c to permit activa-
tion of caspases. Subsequently, 100 μl of caspase buffer
(20 mM Pipes, 100 mM NaCl, 10 mM DTT, 1 mM EDTA,
0.1% w/v CHAPS, 10% w/v sucrose, pH 7.2) containing
100 μM zDEVD-afc (benzyloxycarbonyl-Asp(OMe)-Glu
(OMe)-Val-DL-Asp(OMe)-7-aminotrifluoromethylcouma-
rin, Merck Millipore) or zIETD-afc benzyloxycarbonyl-
Ile-Glu(OMe)-Thr-DL-Asp(OMe)-7-aminotrifluoromethyl
coumarin (Merck Millipore) were added to 10 μl of cyto-
solic extract (10 μg protein) and incubated at 37°C. The
release of afc was measured as emission at 505 nm upon
excitation at 405 nm using an Infinite M200 fluorime-
ter equipped with a thermostated plate reader (Tecan,
Crailsheim, Germany). For measurements of podocyte
death, viable and dead cells were detached with trypsin
and counted in a Neubauer chamber after 0.1% w/v
trypan blue (Life Technologies) staining. The percen-
tage of dead cells was calculated and plotted as mean +/−
SEM, n = 12 per condition. To analyze cellular and nu-
clear morphology, cells were stained with Hoechst dye
(10 μg/ml, Life Technologies) for 5 min and DNA conden-
sation in UCH-L1 tet-on podocytes with or without in-
duced UCH-L1 overexpression for 72 hours was evaluatedunder an Axio Observer A1 microscope (Zeiss) using the
axiovision software (Zeiss).
Analysis of TNF-induced cell death in podocytes
Differentiated sh627 and scrambled shRNA control po-
docytes were plated at a density of 104 cells per 6-well
plate. After 48 hours, cells were treated with 100 ng/ml
murine TNF (PeproTech, Hamburg, Germany) with ad-
dition of 50 μM zVAD-fmk or vehicle (ethanol) as con-
trol for 3 hours. Cells were detached with trypsin and
the amount of dead and living cells was counted in a
Neubauer chamber following staining with 0.1% w/v try-
pan blue. The percentage of dead cells was calculated
and plotted as mean +/− SEM, n = 12 per condition.
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